CLINICAL PROFILE, RISK FACTORS AND VISUAL OUTCOME IN PATIENTS OF ACUTE CENTRAL SEROUS CHORIORETINOPATHY IN A TERTIARY HEALTH CARE CENTRE IN NORTHERN INDIA.
-
Published:2021-05-01
Issue:
Volume:
Page:67-69
-
ISSN:
-
Container-title:INDIAN JOURNAL OF APPLIED RESEARCH
-
language:en
-
Short-container-title:IJAR
Author:
Ajmani Upasna1, Kaur Prempal2, Kumar Dinesh1
Affiliation:
1. Junior resident, Department of Ophthalmology, Government Medical College, Amritsar, Punjab , India. 2. Professor, Department of Ophthalmology, Government Medical College, Amritsar, Punjab , India
Abstract
Central Serous Chorioretinopathy(CSCR) is predominantly idiopathic and self limiting macular disease . Present study
was planned to determine clinical prole and the factors contributing in nal visual outcome in CSCR.. Retrospective
observational study was done on 65 eyes of 53 patients over a period of 2 years. Their best corrected visual acuity(BCVA), color vision,
metamorphopsia and mean central macular thickness(CMT) at presentation were compared with values at 6 months follow-up. Mean age of
patients was 38 years ± 5.43 years. 79.24% patients were males and 77.36% had unilateral involvement. 30.19% patients gave history suggestive
of one or more potential risk factors. The mean BCVA improved from 20/80 at presentation to 20/20 and 20/25 in patients with isolated and CSCR
with PED respectively at 6 months. The mean CMT reduced signicantly in both isolated CSCR and when associated with PED at 6 months.
Color vision defects in 46(70.77%) eyes and metamorphopsia in 49(75.38%) eyes at presentation persisted in 7(10.7%) eyes and 20(30.76%)eyes
respectively at 6 months. Final visual outcome signicantly correlated with visual acuity at presentation.
CONCLUSION: BCVA at presentation strongly predicts nal visual prognosis. Patients need to be counselled regarding persistence of color
vision decits and metamorphopsia.
Publisher
World Wide Journals
Reference21 articles.
1. Latha, Y. J. S., Madhavi, C., & Kumar, M. A. (2015). Visual outcome of central serous retinopathy. International Journal of Research in Medical Sciences, 3(8), 1885-1888. 2. Nicholson, B., Noble, J., Forooghian, F., & Meyerle, C. (2013). Central serous chorioretinopathy: update on pathophysiology and treatment. Survey of ophthalmology, 58(2), 103-126. 3. Kitzmann, A. S., Pulido, J. S., Diehl, N. N., Hodge, D. O., & Burke, J. P. (2008). The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology, 115(1), 169-173. 4. Kim, G. A., Rim, T. H., Lee, S. C., Byeon, S. H., Koh, H. J., Kim, S. S., & Lee, C. S. (2015). Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye, 29(6), 732-741. 5. Teussink, M. M., Breukink, M. B., van Grinsven, M. J., Hoyng, C. B., Klevering, B. J., Boon, C. J., ... & Theelen, T. (2015). OCT angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy. Investigative ophthalmology & visual science, 56(9), 5229-5237.
|
|